Halozyme Therapeutics, Inc.
HALO
$71.48
$0.751.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.51B | 1.40B | 1.24B | 1.18B | 1.08B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.51B | 1.40B | 1.24B | 1.18B | 1.08B |
| Cost of Revenue | 351.86M | 310.26M | 262.09M | 257.48M | 254.23M |
| Gross Profit | 1.16B | 1.09B | 980.76M | 921.19M | 830.08M |
| SG&A Expenses | 208.91M | 193.39M | 172.31M | 167.47M | 161.56M |
| Depreciation & Amortization | 88.41M | 76.66M | 71.05M | 71.05M | 71.05M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 649.18M | 580.32M | 505.45M | 496.00M | 486.84M |
| Operating Income | 859.28M | 816.29M | 737.40M | 682.67M | 597.47M |
| Income Before Tax | 503.37M | 466.88M | 745.94M | 692.13M | 604.93M |
| Income Tax Expenses | 154.53M | 149.99M | 150.45M | 134.85M | 119.57M |
| Earnings from Continuing Operations | 348.84 | 316.89 | 595.49 | 557.28 | 485.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 348.84M | 316.89M | 595.49M | 557.28M | 485.36M |
| EBIT | 859.28M | 816.29M | 737.40M | 682.67M | 597.47M |
| EBITDA | 953.01M | 897.84M | 813.28M | 758.60M | 673.22M |
| EPS Basic | 2.92 | 2.61 | 4.90 | 4.48 | 3.86 |
| Normalized Basic EPS | 4.51 | 4.28 | 3.81 | 3.46 | 2.98 |
| EPS Diluted | 2.78 | 2.49 | 4.75 | 4.37 | 3.76 |
| Normalized Diluted EPS | 4.40 | 4.19 | 3.70 | 3.38 | 2.92 |
| Average Basic Shares Outstanding | 474.38M | 479.45M | 488.18M | 497.81M | 503.59M |
| Average Diluted Shares Outstanding | 487.04M | 490.81M | 502.11M | 509.92M | 514.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |